BREAKING NEWS
Medical White Papers
Presented by
Source: The National Institute for Health and Care Excellence (NICE), USA  Jul 15, 2019
The National Institute for Health and Care Excellence (NICE) has made a major change in the blood pressure guidance(last upated and published in 2011). The new guidelines  recommend the reduction of the threshold of hypertension treatment. This will result in another 280,000 women and 450,000 men in the US, in addition to current figures, being eligible for blood pressure treatment. Theref...
Source: AZ Urogynecology and Pelvic Health Center  Apr 17, 2019
Interstitial Cystitis (IC) is a medical disorder where patients experience urgent and frequent urination and bladder pain in absence of a bladder infection. IC symptoms can result in poor quality of life with depression, sexual dysfunction, anxiety, sleep dysfunction, and stress.   Typically, patients will suffer with painful urination, bladder pain, urgent or frequent urination and even af...
Source: Ionicon Analytik Ges.m.b.H.  Mar 11, 2019
Over the last few years, a developing field of research has emerged in breath gas analysis of volatile organic compounds (VOCs). This technique is non-invasive and has a number of possible applications, including monitoring of metabolic processes, study of pharmacokinetics, screening for disease biomarkers and drug testing. Advantages of IONICON PTR-TOFMS The detection limits and linearity ran...
Source: Albumedix Ltd  Feb 17, 2019
Overcoming Formulation Challenges of Biotherapeutics The increasing study of vaccines and biotherapeutics gives promise for improvement of treatments against various diseases. While protein engineering has shown a great level of growth, several of these therapies persist in the face of ex vivo uncertainty challenges (both physical and chemical instability) which are a source of dosage form inadequ...
Author : Mitchel.L .Zoler, MDedge News  Jan 14, 2019
AHA 2019 CONFERENCE COVERAGE   REPORTING FROM THE AHA SCIENTIFIC SESSIONS CHICAGO – When the first results from a large trial that showed profound and unexpected benefits for preventing heart failure hospitalizations associated with use of the antihyperglycemic sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin came out – a little over 3 years ago – the gen...